Core Viewpoint - Tiger Med's stock price has experienced fluctuations, with a year-to-date increase of 11.41% but a recent decline of 6.40% over the past five trading days [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1] - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] - The revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1] Financial Performance - As of June 30, 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed in the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 4.14% to 51,500 [2] - The top circulating shareholders include China Europe Medical Health Mixed A, holding 27.634 million shares, and Hong Kong Central Clearing Limited, holding 23.266 million shares, with respective changes in holdings noted [3]

Company Overview - Tiger Med is a clinical research service provider based in Hangzhou, China, specializing in I-IV phase clinical trials, data management, and medical testing services [1][2] - The company was established on December 15, 2004, and went public on August 17, 2012 [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has distributed a total of 2.46 billion yuan in dividends since its A-share listing, with 1.15 billion yuan distributed over the last three years [3] Stock Performance - As of September 15, Tiger Med's stock price increased by 2.02% to 62.24 yuan per share, with a market capitalization of 53.59 billion yuan [1] - Year-to-date, the stock has risen by 14.58%, but it has seen a decline of 7.37% over the last five trading days and 10.45% over the last 20 days [1] Shareholder Structure - As of June 30, 2025, Tiger Med had 51,500 shareholders, a decrease of 4.14% from the previous period [2] - The top shareholders include various funds, with notable changes in holdings among major institutional investors [3]

Group 1 - The core point of the news is that Tiger Med's stock has experienced a decline, with a cumulative drop of 9.2% over the last four days, closing at 61.01 yuan per share on September 12, with a total market capitalization of 52.531 billion yuan [1] - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV clinical trials, data management, and other related services [1] - The company's main revenue sources include clinical trial-related services and laboratory services (52.60%), clinical trial technical services (45.21%), and other services (2.19%) [1] Group 2 - Morgan Fund holds a position in Tiger Med through the Morgan CSI Innovative Drug Industry ETF (560900), which reduced its holdings by 3,000 shares in the second quarter, now holding 18,100 shares, accounting for 2.76% of the fund's net value [2] - The Morgan CSI Innovative Drug Industry ETF has a total scale of 34.9084 million, with a year-to-date return of 40.82% and a one-year return of 60.71% [2] - The fund manager, Mao Shichao, has been in position for 5 years and 128 days, with the fund's best return during this period being 56.22% and the worst being -24.75% [3]

Market Overview - The Hong Kong stock market experienced a collective pullback, with the Hang Seng Index down 0.43% to 26,086.32 points, the Tech Index down 0.24% to 5,888.77 points, and the National Enterprises Index down 0.73% to 9,260.25 points [1][2]. Semiconductor Sector - The semiconductor sector led the market with notable gains, including InnoCare (02577.HK) up 9.25%, SMIC (00981.HK) up 4.97%, and Shanghai Fudan (01385.HK) up 5.37% [4][5]. - TSMC reported a revenue of NT$335.77 billion for August 2025, marking a year-on-year increase of 33.8% and a quarter-on-quarter increase of 3.9%, boosting market expectations for AI infrastructure development [6]. Telecommunications Equipment - Telecommunications equipment stocks also saw strong performance, with ZTE (00763.HK) up 7.50%, and China Tower (00788.HK) up 3.19% [8]. Nonferrous Metals - Nonferrous metal stocks were buoyed by interest rate cut expectations, with Jinli Permanent Magnet (06680.HK) up 6.04% and Luoyang Molybdenum (03993.HK) up 4.79% [9][10]. - Minsheng Securities noted that industrial metal supply remains constrained while domestic demand remains resilient, suggesting a potential upward trend in metal prices [11]. Cement Sector - The cement sector benefited from price increases, with Huaxin Cement (06655.HK) up 4.94% and China National Building Material (03323.HK) up 3.38% [12][13]. - Research indicated that cement prices in the Pearl River Delta region are expected to rebound due to seasonal demand and reduced supply [14]. Pharmaceutical Sector - Pharmaceutical stocks faced downward pressure, with Tigermed (03347.HK) down 9.36% and Zai Lab (06160.HK) down 5.87% [15][16]. - Market rumors about potential restrictions on innovative drugs from China to the U.S. have not significantly altered long-term expectations for these companies [17][18]. New Consumption Sector - New consumption stocks showed weakness, with Maogeping (01318.HK) down 4.73% and Laopu Gold (06181.HK) down 3.51% [19][20]. - Despite the current underperformance, institutions remain optimistic about the growth potential of new consumption companies, driven by changing consumer behaviors among the Z generation [21]. Individual Stock Movements - China Gold International (02099.HK) rose 2.70% amid increasing expectations for U.S. interest rate cuts [22]. - Tenghong Precision (06088.HK) surged 12.79% following the announcement of new Apple products, including new iPhones and AirPods [23][24].

Core Viewpoint - The Hong Kong pharmaceutical sector experienced significant declines, with major companies facing substantial stock price drops on September 11. Company Performance - Tigermed (03347.HK) saw a decline of 14.06% - Viva Biotech (01873.HK) dropped by 11.85% - Kanglong Chemical (03759.HK) fell by 10% - Zai Lab (06172.HK) decreased by 8.26% [1]

Company Overview - Tiger Med is located in Hangzhou, Zhejiang Province, and was established on December 15, 2004, with its IPO on August 17, 2012 [1] - The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products, covering I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has cumulatively distributed 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Stock Performance - As of September 9, Tiger Med's stock price was 65.83 yuan per share, with a market capitalization of 56.681 billion yuan [1] - Year-to-date, the stock price has increased by 21.18%, but it has seen a decline of 0.63% over the last five trading days and 1.78% over the last twenty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders was 51,500, a decrease of 4.14% from the previous period [2] - The top ten circulating shareholders include notable funds, with changes in their holdings indicating varying levels of investment interest [3]

Group 1 - The company, Tigermed, announced that it will hold its first extraordinary general meeting of shareholders for 2025 on September 29, 2025 [2] - The meeting will review multiple proposals, including the proposal for amendments [2]

证券代码：300347 证券简称：泰格医药 公告编码（2025）037 号 杭州泰格医药科技股份有限公司 关于召开 2025 年第一次临时股东会的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 一、召开会议的基本情况 1．股东会届次：2025年第一次临时股东会。 2．股东会的召集人：公司董事会。 3．会议召开的合法、合规性：经公司第五届董事会第十八次会议审议通过，决定召 开2025年第一次临时股东会，召集程序符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 4．会议召开的日期、时间： 现场会议召开日期和时间：2025 年9 月29 日（星期一）下午15:00 网络投票日期和时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 9 月 29 日上午 9:15—9:25，9:30—11:30 和下午13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年9 月29 日上午 9:15 至2025 年9 月29 日下午15:00。 5．会议的召开方式：本次股东会采用现场表决与网 ...

杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 2025年9月29日（星期一）舉行的2025年第一次臨時股東大會代表委任表格 本人╱ 吾等 1 地址為 為杭州泰格醫藥科技股份有限公司（「本公司」）股本中每股面值人民幣1.00元股份 股 2 H股登記持有人，茲委任大會主席 3 或 地址為 HANGZHOU TIGERMED CONSULTING CO., LTD. 日期：2025年 月 日 簽署 5 ： 附註： 收集個人資料聲明 本代表委任表格所指的「個人資料」具有《個人資料（私隱）條例》（第486章）（「私隱條例」）賦予「個人資料」之相同 涵義，當中包括 閣下及 閣下代表的姓名及地址。 為本人╱ 吾等的受委代表，代表本人╱ 吾等出席本公司謹訂於2025年9月29日（星期一）下午 三時正假座中國杭州市濱江區聚工路19號盛大科技園A座18樓會議室舉行2025年第一次臨 時股東大會（「臨時股東大會」）及其任何續會，以考慮及酌情通過載於臨時股東大會通告的 決議案，並於臨時股東大會及其任何續會代表本人╱ 吾等並以本人╱ 吾等名義就下述決議 案按以下方式投票。除非另有說明 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 2025年第一次臨時股東大會通告 茲通告 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）謹 定 於2025年9月29日 （星 期 一）下 午 三 時 正 假 座 中 國 杭 州 市 濱 江 區 聚 工 路19號盛大科技園A座 18樓會議室舉行2025 年 第 一 次 臨 時 股 東 大 會（「臨時股東大會」）或 其 任 何 續 會，藉 以 考 慮 並 酌 情 批 准 下 列 決 議 案。除 文 義 另 有 所 指 外，本 通 告 所 用詞彙與本公司日期為2025年9月9日（星 期 二）之 通 函（「通 ...